Delivery Order SPE2DB22D9316-SPE2DB26FYM52
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,513.54 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 ml vials. The award, issued on November 5, 2025, with an ultimate completion date of November 28, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $5,027.08 to DMS Pharmaceutical Group Inc. for EYLEA 2 mg/0.05 mL vials on October 29, 2025, with completion scheduled for November 20, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price contract structure with no set-aside designation. This delivery order represents one of numerous purchases issued to the...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $34,224.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 mL syringes. The award was issued on October 27, 2025, with an ultimate completion date of November 18, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a $2,513.56 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Eylea 2 mg/0.05 ml vials. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specialized pharmaceutical procurement under DLA's broader pharmaceutical supply mission. This award carries no set-aside designation,...
- The Defense Logistics Agency awarded a $20,220 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA HD 8 mg/0.07 mL vials. The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, contains no set-aside designation, indicating the award was made through competitive procurement. DMS Pharmaceutical Group Inc. will serve as the...
- The Defense Logistics Agency's Medical Supply Chain awarded a $3,666.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EYLEA 2MG/0.05ML syringes. The award, issued on October 20, 2025, with an ultimate completion date of October 20, 2025, contains no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was...
- The Defense Logistics Agency awarded a delivery order valued at $12,567.70 to DMS Pharmaceutical Group Inc. for the supply of EYLEA (2 mg/0.05 mL vials). The award, issued on June 2, 2025, with an ultimate completion date of June 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million through November 2026, which...
- The U.S. Defense Logistics Agency (DLA) awarded a $3,940.44 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, which has a completion date of July 18, 2024, is for the supply of EYLEA 2 MG/0.05 ML VIAL 0.05ML, a pharmaceutical product used to treat certain medical conditions. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to...
- The U.S. Defense Logistics Agency (DLA), operating under the Medical Supply Chain, awarded a $29,335.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, issued July 7, 2025 with completion targeted for July 28, 2025, covers the supply of EYLEA 2 mg/0.05 mL syringes. This award was made without set-aside designation, leveraging the vendor's competitive positioning as a...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA HD 8 mg/0.07 ml vials. This firm fixed-price delivery order, valued at $19,812.70, represents a direct distribution of this specialty pharmaceutical product to support Department of Defense healthcare requirements. The award was issued on September 14, 2025, with an ultimate completion date of October...
- SPE2DB22D9316Indefinite Delivery Contract
- SPE2DB22D9316-SPE2DB26FYM52Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,027.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 mL vials. This firm fixed-price delivery order, issued on November 5, 2025, with completion targeted by November 28, 2025, carries no set-aside designation, indicating the award was made through open competition. The order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition vehicle designed to provide comprehensive pharmaceutical support to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier to federal agencies since its registration in the System for Award Management in 2001. The company's portfolio encompasses a broad range of pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. Under its prime vendor contract SPE2DR with a $500 million ceiling and completion date of December 31, 2036, the company is positioned to continue delivering diverse pharmaceutical requirements to support recurring medical supply needs across the global military medical system. No subcontractors are identified in the award documentation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 11/5/25 |